Covidien issues its final quarterly report as a standalone company, saying its fiscal 1st-quarter earnings beat expectations and it prepares for a $43 billion acquisition by Medtronic next week.
Law firm Greenberg Traurig, MassMEDIC and LB Ventures created Medtech Partnering Day with an eye on putting start-ups and medtech titans together in the same room.
You can't do M&A without a little meet & greet.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic CEO: 'Covidien deal will help us do for ORs what we've done for cath labs'; Medtronic details shareholder votes for Covidien merger; CardioMEMS, Nevro among top 20 VC-backed healthcare exits of 2014; Medtronic-Covidien merger could close this month; Covidien's Stellarex drug-eluting balloon wins CE Mark
Here's a look at some of the top regulatory stories for medical device companies this week: Another recall for Covidien's Nellcor ventilator business; MiMedx reveals subpoena, lawsuit against rival, beefs with FDA; Quanta wins CE Mark for portable dialysis device; Cohera Medical wins approvable letter from FDA for TissuGlu surgical sealant; FDA lifts import ban on Hospira infusion pumps
Medtronic CEO Omar Ishrak highlights how the Covidien buyout will enable his company to expand its value-based model into the operating room.
Almost exactly a year ago Medtronic (NYSE:MDT) CEO Omar Ishrak insisted that value-based healthcare is the salvation, not the damnation, of the medical device industry.
Medtronic and Covidien could close their $43 billion mega-merger by the end of the month, according to a regulatory filing.
Medtronic's shareholders overwhelmingly approved its proposed, $43 billion merger with Covidien this week, including a controversial provision to cover a portion of its executives tax bills.